Arcus Biosciences, Inc. (RCUS) by event type
RCUS moves most on analyst upgrades — a median of -1.67% at 30 minutes across 10 measured events. Each row is measured over the last three years and read against the price at its own news timestamp. Back to the RCUS overview →
How RCUS reacts across 5 measured event types.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades 2,679 of 2,717 | 10 | -1.67% | 20% | +1.04% |
| Coverage initiations 2,134 of 2,283 | 13 | -1.14% | 39% | -2.94% |
| Rating reiterations 1,284 of 3,522 | 69 | +0.04% | 51% | -0.10% |
| Price-target raises 75 of 1,790 | 12 | +0.40% | 58% | +0.63% |
| Price-target cuts 18 of 1,527 | 14 | +0.76% | 86% | -0.63% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The rank under each event type orders every name measured for it by median 30-min reaction, most positive first — so a low rank on a downgrade means this name falls harder than most, not that it moves less. Names with an identical median share a rank; a name the cross-section does not carry shows no rank rather than a guessed one. 1 further class was observed with fewer than 10 measured events and is not published.
That’s how RCUS usually reacts — get an email when it moves on news →Every name measured for these event types: Analyst upgrades → · Coverage initiations → · Rating reiterations → · Price-target raises → · Price-target cuts → · RCUS overview →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Penumbra, Inc. (PEN) | 369 | +0.06% | 60% |
| Kura Oncology, Inc. (KURA) | 368 | -0.13% | 49% |
| Ligand Pharmaceuticals Incorporated (LGND) | 367 | +0.06% | 52% |
| Microbot Medical Inc. (MBOT) | 366 | -0.19% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.